JP2002526408A - 疼痛および不安の処置のためのmglur5アンタゴニスト - Google Patents

疼痛および不安の処置のためのmglur5アンタゴニスト

Info

Publication number
JP2002526408A
JP2002526408A JP2000573360A JP2000573360A JP2002526408A JP 2002526408 A JP2002526408 A JP 2002526408A JP 2000573360 A JP2000573360 A JP 2000573360A JP 2000573360 A JP2000573360 A JP 2000573360A JP 2002526408 A JP2002526408 A JP 2002526408A
Authority
JP
Japan
Prior art keywords
antagonist
mglur
pain
mglur5
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000573360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002526408A5 (cg-RX-API-DMAC7.html
Inventor
ハンス・アルガイアー
ニコラス・デイビッド・コスフォード
ペーター・ヨーゼフ・フローア
ファブリツィオ・ガスパリーニ
コンラート・ゲンチュ
スティーブン・ディ・ヘス
エドウィン・カール・ジョンソン
ライナー・クーン
マーク・トリックルバンク
ラズロ・アーバン
マーク・アンドリュー・バーニー
ゴニュル・ベリセレビ
キャサリン・ウォーカー
Original Assignee
ノバルティス アクチエンゲゼルシャフト
シビア・ニューロサイエンシーズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002526408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by ノバルティス アクチエンゲゼルシャフト, シビア・ニューロサイエンシーズ・インコーポレイテッド filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2002526408A publication Critical patent/JP2002526408A/ja
Publication of JP2002526408A5 publication Critical patent/JP2002526408A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
JP2000573360A 1998-10-02 1999-09-30 疼痛および不安の処置のためのmglur5アンタゴニスト Pending JP2002526408A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
US22081398A 1998-12-23 1998-12-23
US9821503.1 1998-12-23
US09/220,813 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (2)

Publication Number Publication Date
JP2002526408A true JP2002526408A (ja) 2002-08-20
JP2002526408A5 JP2002526408A5 (cg-RX-API-DMAC7.html) 2006-11-24

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000573360A Pending JP2002526408A (ja) 1998-10-02 1999-09-30 疼痛および不安の処置のためのmglur5アンタゴニスト

Country Status (21)

Country Link
EP (1) EP1117403B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002526408A (cg-RX-API-DMAC7.html)
KR (1) KR20010088832A (cg-RX-API-DMAC7.html)
CN (1) CN1187048C (cg-RX-API-DMAC7.html)
AT (1) ATE255894T1 (cg-RX-API-DMAC7.html)
AU (1) AU765644B2 (cg-RX-API-DMAC7.html)
BR (1) BR9914215A (cg-RX-API-DMAC7.html)
CA (1) CA2345137A1 (cg-RX-API-DMAC7.html)
DE (1) DE69913548T2 (cg-RX-API-DMAC7.html)
DK (1) DK1117403T3 (cg-RX-API-DMAC7.html)
ES (1) ES2213389T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0200553A3 (cg-RX-API-DMAC7.html)
ID (1) ID29095A (cg-RX-API-DMAC7.html)
IL (2) IL142047A0 (cg-RX-API-DMAC7.html)
NO (1) NO20011440L (cg-RX-API-DMAC7.html)
NZ (1) NZ510743A (cg-RX-API-DMAC7.html)
PL (1) PL202906B1 (cg-RX-API-DMAC7.html)
PT (1) PT1117403E (cg-RX-API-DMAC7.html)
RU (1) RU2232017C2 (cg-RX-API-DMAC7.html)
SK (1) SK4382001A3 (cg-RX-API-DMAC7.html)
WO (1) WO2000020001A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533102A (ja) * 2005-03-18 2008-08-21 ピエール・ファーブル・メディカマン 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
ATE297734T1 (de) 2000-12-22 2005-07-15 Hoffmann La Roche Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
DK2083811T3 (en) 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
AU2016273751B2 (en) 2015-06-03 2020-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
EP3459939A1 (en) 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2056983T3 (es) * 1988-03-21 1994-10-16 Boehringer Ingelheim Pharma Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5001019839, FUNDYTUS M E, NEUROREPORT, 19980309, V9N4, P731−735 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533102A (ja) * 2005-03-18 2008-08-21 ピエール・ファーブル・メディカマン 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用
JP2013173759A (ja) * 2005-03-18 2013-09-05 Pierre Fabre Medicament 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用

Also Published As

Publication number Publication date
CN1321087A (zh) 2001-11-07
DE69913548D1 (de) 2004-01-22
BR9914215A (pt) 2001-07-03
NO20011440L (no) 2001-05-15
SK4382001A3 (en) 2001-08-06
EP1117403B1 (en) 2003-12-10
HUP0200553A3 (en) 2002-11-28
AU6198499A (en) 2000-04-26
NZ510743A (en) 2003-10-31
KR20010088832A (ko) 2001-09-28
ES2213389T3 (es) 2004-08-16
EP1117403A1 (en) 2001-07-25
CA2345137A1 (en) 2000-04-13
PL346876A1 (en) 2002-03-11
DE69913548T2 (de) 2004-09-23
IL142047A (en) 2007-09-20
IL142047A0 (en) 2002-03-10
HUP0200553A2 (hu) 2002-07-29
AU765644B2 (en) 2003-09-25
NO20011440D0 (no) 2001-03-21
ID29095A (id) 2001-07-26
PL202906B1 (pl) 2009-08-31
PT1117403E (pt) 2004-04-30
DK1117403T3 (da) 2004-04-13
RU2232017C2 (ru) 2004-07-10
WO2000020001A1 (en) 2000-04-13
CN1187048C (zh) 2005-02-02
ATE255894T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
AU765644B2 (en) mGluR5 antagonists for the treatment of pain and anxiety
KR20170003527A (ko) 경구 투여용 펜토산 폴리설페이트 염의 조성물
JP2003530429A (ja) αアドレナリン受容体活性を調節するための方法および組成物
JP2012131829A (ja) そう痒状態の処置のためのmglur5アンタゴニストの使用
US20010056084A1 (en) MGluR5 antagonists for the treatment of pain and anxiety
JP3832229B2 (ja) フェニルエテンスルホンアミド誘導体含有医薬
KR20190019171A (ko) 섬유증 치료에서 사용하기 위한 wnt 억제제
AU2006230674A8 (en) Methods for the Treatment of Synucleinopathies
RU2510273C2 (ru) Меквитазин для лечения или предотвращения патологий, в которых задействованы н4 рецепторы гистамина
EP2066323A2 (en) Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein
WO2023199010A1 (en) Treatment of muscle fibrosis
JP2021532188A (ja) μオピオイド受容体のアロステリックモジュレーター
WO2000037089A1 (en) Cyclic adenosine diphosphate ribose analogues for modulating t cell activity
US20130203789A1 (en) Novel Inhibitors of LYN Kinase and Methods Using Same
JP2005247843A (ja) 掻痒治療剤
HK1148667B (en) Mequitazine for treating or preventing pathologies involving histamine h4 receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100312

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100720